Forte Biosciences (FBRX) Gains from Investment Securities (2016 - 2017)

Forte Biosciences' (FBRX) quarterly Gains from Investment Securities came in at $22000.0 in Q2 2017, up 181.48% year-on-year from $7815.8 in Q2 2016, and up 137.29% on a QoQ basis from -$59000.0 in Q1 2017.

Forte Biosciences (FBRX) Gains from Investment Securities (2016 - 2017) Analysis & Trends

Forte Biosciences (FBRX) has 2 years of Gains from Investment Securities data on file, last reported at $22000.0 in Q2 2017.

  • On a quarterly basis, Gains from Investment Securities rose 181.48% year-over-year to $22000.0 in Q2 2017; TTM through Dec 2017 was -$37000.0, a 26.0% increase from a year earlier, with the FY2017 full-year figure at -$37000.0, up 26.0% from the prior year.
  • Gains from Investment Securities for Q2 2017 stood at $22000.0, up from -$59000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for FBRX reached as high as $22000.0 in Q2 2017 and fell as low as -$59000.0 in Q1 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Forte Biosciences 1.37 Bn 1.31 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2017 22,000.00
Jun 30, 2017 22,000.00
Mar 31, 2017 -59,000.00
Mar 31, 2017 -59,000.00
Dec 31, 2016 -32,000.00
Dec 31, 2016 -32,000.00
Sep 30, 2016 11,000.00
Sep 30, 2016 11,000.00
Jun 30, 2016 -27,000.00
Jun 30, 2016 -27,000.00
Mar 31, 2016 -2,000.00
Mar 31, 2016 -2,000.00